Fulcrum Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – FULC
NEW YORK, NY / ACCESSWIRE / September 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws. Fulcrum announced on September 12, 2024, that "its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did […]